Enter your email address in the box to the right of this page to receive email updates from the Life Sciences Hub when new content is published.
For those with an interest in life sciences, the rise to prominence of CRISPR, a transformational development in the field of molecular biology and genetics, has been impossible to ignore.
Welcome to our blog dedicated to Life Sciences. We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector. We focus on (bio)pharmaceuticals and medical technologies, and also cover food and beverages, cosmetics and other healthcare products.
29 November 2019 - Posted by: Marc Döring
The past few years have seen a global trend towards the liberalisation of cannabis policies, with cannabis becoming legalised in numerous countries and US states for recreational and/or medical use. Cannabis is currently authorised for medicinal use in more than 25 countries, including Australia, Canada, Germany, the Netherlands and the UK. And while recreational use › Read More
27 November 2019 - Posted by: Jacqueline Bore
The Medical Devices Regulation, the “MDR”, which comes largely into force in May 2020, will introduce significant changes to the way in which software used in a medical context will be regulated in the European Union. The medical devices industry has been eagerly awaiting additional guidance on how these new provisions are likely to be › Read More
22 November 2019 - Posted by: Zuzana Hecko
In August 2019, the Slovak government introduced a draft law which suggested removing CBD (cannabidiol) from the list of psychotropic substances. The draft law therefore attempted to make CBD a non-regulated substance. The draft law was, however, subsequently rejected by the Slovak parliament. Act No. 139/1998 Coll. (the Narcotics Act) places CBD in the same › Read More
21 November 2019 - Posted by: Eveline Van Keymeulen
In order to ensure savings for the healthcare system in 2020, French legislators are encouraging biosimilar uptake and price cuts. The draft 2020 Social Security Financing Bill (2020 PLFSS) introduces new measures that tackle tactics developed by medicinal product originators, which consist of offering low prices for biological brands to healthcare institutions as a way › Read More
14 November 2019 - Posted by: Eveline Van Keymeulen
Following the shortage of medicines announcement made on 25 September 2019 by the French Prime Minister and the Minister of Health (See our previous blog posts: French government determined to sanction pharmaceutical companies for shortages of medicines and Draft 2020 Social Security Financing Bill encourages price cuts and biosimilar uptake), the French pharmaceutical industry association › Read More